Table 1.
Patient demographics and outcomes
| No. of patients (n) | |
|---|---|
| Sex | |
| Male | 20 |
| Female | 13 |
| Age | |
| Mean | 59.79 |
| Median | 63 |
| Range | 38–71 |
| ECOG performance status | |
| 0 | 13 |
| 1 | 20 |
| Primary site | |
| Colon | 14 |
| Rectum | 7 |
| Lung | 4 |
| Breast | 3 |
| Pancreas | 2 |
| Appendix | 1 |
| Esophagus | 1 |
| Bladder | 1 |
| Location of metastatic site(s) | |
| Lung | 16 |
| Liver | 16 |
| Lymph node | 8 |
| Kidney/Adrenal | 3 |
| Abdomen | 3 |
| Pelvis | 2 |
| Stomach | 2 |
| Spinal | 2 |
| Brain | 2 |
| Other | 3 |
| HLA-A2 | |
| Positive | 14 |
| Negative | 11 |
| Unknown | 8 |
| Prior treatments received | |
| Surgery | 25 |
| Radiation | 12 |
| Chemotherapy—0 prior regimens | 0 |
| Chemotherapy—1 prior regimen | 2 |
| Chemotherapy—2 prior regimens | 31 |
| Chemotherapy—>2 prior regimens | 29 |
| Response to therapy | |
| Partial response | 0 |
| Stable disease | 8 |
| Progressive disease | 21 |
| Not evaluable | 4 |
| Progression-free survival (mo) | |
| Median | 1.8 |
| Range | 0.8–15.7 |
| Overall survival (mo) | |
| Median | 6.3 |
| Range | 1.2–98.8 |